Linezolid Dry Suspension has antimicrobial properties and is effective primarily against aerobic Gram-positive bacteria. Linezolid Dry Suspension belongs to the oxazolidinone class of synthetic antibiotics and can be used for the treatment of infections caused by aerobic Gram-positive bacteria, specifically for nosocomial or community-acquired pneumonia caused by sensitive strains of specific microorganisms, complicated or non-complicated skin and soft-tissue skin infections, and vancomycin-resistant enterococcal infections of fecal coliform bacteria, including concomitant bacteremia. The drug should be contraindicated in persons with known hypersensitivity to the product, in persons with uncontrolled hypertension, in patients with carcinoid syndrome, in persons with pheochromocytoma, in patients with carcinoid tumors, in patients with hyperthyroidism, in persons who are using or have used within the last two weeks a monoamine oxidase inhibitor. The most common adverse events following administration are headache, nausea, diarrhea, and oral and vaginal candidiasis. Specific medications should be administered under the supervision of a specialist.